Holen Sie sich die Stockscreener-App
2.325
14.13%
-0.395
Schlusskurs vom Vortag:
$2.72
Offen:
$2.66
24-Stunden-Volumen:
138.44K
Relative Volume:
3.70
Marktkapitalisierung:
$32.79M
Einnahmen:
$52.16M
Nettoeinkommen (Verlust:
$-48.60M
KGV:
-2.5549
EPS:
-0.91
Netto-Cashflow:
$-77.48M
1W Leistung:
-25.61%
1M Leistung:
-41.46%
6M Leistung:
-72.75%
1J Leistung:
-49.21%
1-Tages-Spanne:
$2.19
$2.75
1-Wochen-Bereich:
$2.19
$3.25
52-Wochen-Spanne:
$2.19
$11.30
Hookipa Pharma Inc Stock (HOOK) Company Profile
Firmenname
Hookipa Pharma Inc
Sektor
Branche
Telefon
0114318906360
Adresse
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY
Vergleichen Sie HOOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| HOOK | 2.325 | 32.79M | 52.16M | -48.60M | -77.48M | -0.91 |
| VRTX | 450.27 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.65 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.61 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.57 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.17 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-11-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-03 | Eingeleitet | Truist | Buy |
| 2020-10-26 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2019-09-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-05-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Hookipa Pharma Inc Aktie (HOOK) Neueste Nachrichten
Hookipa Pharma stock hits 52-week low at $2.62 amid market challenges - Investing.com
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky - Simply Wall St
HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target - Quantisnow
HOOKIPA Pharma stock target lowered, maintains outlook on strategic direction - Investing.com UK
HOOKIPA Pharma Inc (HOOK) Quarterly 10-Q Report - Quartz
Hookipa Pharma stock hits 52-week low at $3.4 amid market challenges - Investing.com Australia
Hookipa Pharma Reports Q3 Earnings Amid Strategic Changes - TipRanks
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates - The Bakersfield Californian
HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker - Quantisnow
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market By Investing.com - Investing.com UK
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 - Quantisnow
HOOKIPA commences HPV16+ cancer adjuvant care trial - Investing.com India
HOOKIPA commences HPV16+ cancer adjuvant care trial By Investing.com - Investing.com Nigeria
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer - The Manila Times
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator - The Bakersfield Californian
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges By Investing.com - Investing.com South Africa
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges - Investing.com
Hookipa Pharma stock hits 52-week low at $4.06 amid market challenges - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in cancer immunotherapy - Investing.com
HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
HOOKIPA presents KRAS cancer treatment data By Investing.com - Investing.com South Africa
HOOKIPA presents KRAS cancer treatment data - Investing.com India
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset - Marketscreener.com
Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight - GlobeNewswire Inc.
Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm | FinancialContent Business Page - Financial Content
How To Trade (HOOK) - Stock Traders Daily
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet - MSN
HOOKIPA appoints new Non-Executive Chair as two members exit - Investing.com India
HOOKIPA appoints new Non-Executive Chair as two members exit By Investing.com - Investing.com South Africa
HOOKIPA Pharma Announces Board of Directors Changes - citybiz
Hookipa Pharma Announces Board Restructuring and Appointments - TipRanks
HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Update - MarketBeat
Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know - MSN
HOOK (HOOKIPA Pharma) 3-Year FCF Growth Rate : 25.90% (As of Jun. 2024) - GuruFocus.com
HOOK (HOOKIPA Pharma) 3-Year Revenue Growth Rate : -34.30% (As of Jun. 2024) - GuruFocus.com
The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29% - Simply Wall St
HOOKIPA Pharma Second Quarter 2024 Earnings: Revenues Miss Expectations - Yahoo Finance
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
The Globe and Mail - The Globe and Mail
HOOKHOOKIPA Pharma Inc. Latest Stock News & Market Updates - StockTitan
SEC Form 10-Q filed by HOOKIPA Pharma Inc. - Quantisnow
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights - ForexTV.com
Finanzdaten der Hookipa Pharma Inc-Aktie (HOOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):